Information on EC 3.1.4.17 - 3',5'-cyclic-nucleotide phosphodiesterase

New: Word Map on EC 3.1.4.17
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Bacteria, Eukaryota

EC NUMBER
COMMENTARY hide
3.1.4.17
-
RECOMMENDED NAME
GeneOntology No.
3',5'-cyclic-nucleotide phosphodiesterase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of phosphoric ester
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
purine metabolism
-
-
Purine metabolism
-
-
SYSTEMATIC NAME
IUBMB Comments
3',5'-cyclic-nucleotide 5'-nucleotidohydrolase
Acts on 3',5'-cyclic AMP, 3',5'-cyclic dAMP, 3',5'-cyclic IMP, 3',5'-cyclic GMP and 3',5'-cyclic CMP.
CAS REGISTRY NUMBER
COMMENTARY hide
9040-59-9
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
UniProt
Manually annotated by BRENDA team
isoforms PDE1, PDE2, PDE3, PDE7
-
-
Manually annotated by BRENDA team
computational analysis
SwissProt
Manually annotated by BRENDA team
product of Rv0805 gene
Uniprot
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
Rattus norvegicus Sprague-Dawley
-
-
-
Manually annotated by BRENDA team
MAR-1
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
-
in adipocytes, insulin induces formation of macromolecular complexes containing signaling molecules such as IRS-1, PI3K and PKB, proteins involved in PDE3B activation/phosphorylation
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
2',3'-cAMP + H2O
3'-AMP
show the reaction diagram
-
in PdeB the phosphodiesterase activity for 2',3'-cAMP is about 1.7fold higher than that for 3',5'-cAMP
-
-
?
2',3'-cAMP + H2O
5'-AMP
show the reaction diagram
3',5'-cAMP + H2O
5'-AMP
show the reaction diagram
3',5'-cAMP + H2O
adenosine 5'-phosphate
show the reaction diagram
3',5'-cCMP + H2O
5'-CMP
show the reaction diagram
3',5'-cdAMP + H2O
5'-dAMP
show the reaction diagram
-
-
-
-
?
3',5'-cGMP + H2O
5'-AMP
show the reaction diagram
3',5'-cGMP + H2O
5'-GMP
show the reaction diagram
3',5'-cGMP + H2O
guanosine 5'-phosphate
show the reaction diagram
3'-AMP + H2O
?
show the reaction diagram
-
high activity
-
-
?
3'-GMP + H2O
?
show the reaction diagram
-
high activity
-
-
?
5'-ATP + H2O
?
show the reaction diagram
-
-
-
-
?
5'-dAMP + H2O
?
show the reaction diagram
-
low activity
-
-
?
5'-UMP + H2O
?
show the reaction diagram
-
high activity
-
-
?
adenosine 3',5'-cyclic phosphate + H2O
adenosine 5'-phosphate
show the reaction diagram
cAMP + H2O
5'-AMP
show the reaction diagram
-
degradation of extracellular cAMP by isoforms PDE1, PDE7. Degradation of intracellular cAMP by isoform PDE2
-
-
?
cAMP + H2O
AMP
show the reaction diagram
cGMP + H2O
5'-GMP
show the reaction diagram
-
degradation of intracellular cGMP by isoform PDE3
-
-
?
cGMP + H2O
GMP
show the reaction diagram
guanosine 3',5'-cyclic phosphate + H2O
guanosine 5'-phosphate
show the reaction diagram
nucleoside 3',5'-cyclic phosphate + H2O
nucleoside 5'-phosphate
show the reaction diagram
UDP-D-glucose + H2O
?
show the reaction diagram
-
UDP-D-glucose is hydrolyzed by PdeB, but not by PdeA
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
3',5'-cAMP + H2O
5'-AMP
show the reaction diagram
3',5'-cGMP + H2O
5'-GMP
show the reaction diagram
nucleoside 3',5'-cyclic phosphate + H2O
nucleoside 5'-phosphate
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
Calmodulin
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Ba2+
-
40% stimulation at 0.25 mM
CaCl2
-
entirely dependent on the presence of divalent cations, activity with 0.2 mM CaCl2 is 15.9% of maximal activity obtained with 2 mM MgCl2
Cu2+
-
stimulates at 2.5 mM
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-6-(3-(3-cyclopropyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone
-
IC50: 0.0001 mM, PDE3A; IC50: 0.00028 mM, PDE3B
(2R,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
-
IC50: 0.0043 mM, PDE2
(2S,3R)-3-(7-amino-3H-imidazo[4,5-b]pyridin-3-yl)nonan-2-ol
-
-
(2Z)-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one
-
IC50: 0.000006 mM, PDE3; IC50: 0.0012 mM, PDE2; IC50: 0.015 mM, PDE1
(6aS,9aR)-3-benzyl-2-(biphenyl-4-ylmethyl)-5-methyl-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one
-
comparison of inhibitory effect on several recombinant human PDE isoforms. Effective PDE1 inhibitor in cellular context
(Rp)-guanosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate
-
time-dependent and irreversible inactivation of PDE3A
1-(2-methylbenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-(2-methylbenzyl)-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-(3-chlorobenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-(3-chlorobenzyl)-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-(3-methylbenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-(4-chlorobenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-(4-chlorobenzyl)-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-(4-methylbenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-(4-methylbenzyl)-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
1-benzyl-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
-
-
2-cyclohexyl-2-methyl-N1-[3-(2-oxo-1,2-dihydro-6-quinolyl,oxy)propyl]-1-hydrazinecarboxamide
-
IC50: 0.00000034 mM, PDE3A, highly selective PDE3 inhibitor; IC50: 0.0000019 mM, PDE3B; IC50: 0.0.0209 mM, PDE2; IC50: 0.1129 mM, PDE1
2-[[4-[4-pyridin-4-yl-1-(2,2, 2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline succinic acid
3',5'-cGMP
-
-
3'-benzyl-2'-(biphenyl-4-ylmethyl)-5'-methyl-3'H-spiro[cyclopentane-1,7'-imidazo[2,1-b]purin]-4'(5'H)-one
-
comparison of inhibitory effect on several recombinant human PDE isoforms. Effective PDE1 inhibitor in cellular context
3-isobutyl-1-methyl-1H-purine-2,6(3H,7H)-dione
3-isobutyl-1-methylxanthine
3-isobutyl-8-(methoxymethyl)-1-methyl-3,9-dihydro-1H-purine-2,6-dione
-
i.e. 8MM-IBMX, comparison of inhibitory effect on several recombinant human PDE isoforms
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
-
Ro20-1724
5-(2-propoxyphenyl)-2,3-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
-
-
5-(3-cyclopentyloxy-4-methoxy-phenyl)-pyrrolidin-2-one
-
50% inhibition at about 0.1 mM
5-methyl-2-[4-(trifluoromethyl)benzyl]-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[2,1-b]purin-4(1H)-one
-
i.e. SCH51866, comparison of inhibitory effect on several recombinant human PDE isoforms. Effective PDE1 inhibitor in cellular context
6-(3-(3-cyclooctyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone
-
IC50: 0.00000032 mM, PDE3A, highly selective PDE3 inhibitor; IC50: 0.0000015 mM, PDE3B; IC50: 0.0429 mM, PDE1; IC50: 0.0523 mM, PDE2
8-hydroxyquinoline
2 mM, 28% residual activity
8-methoxymethyl(-3-isobutyl-1-)methylxanthine
8-methoxymethyl-3-isobutyl-1-methylxanthine
8-methoxymethyl-isobutylmethylxanthine
-
inhibits activated PDE1 and PDE2 isoforms as well as PDE4 and PDE5, is 3times more potent in inhibiting PDE5 than PDE1
adenine
-
at 2.5 mM, strong
adenosine
amantadine
-
brain 60 kDa isozyme
amrinone
-
IC50: 0.0167 mM, PDE3A; IC50: 0.0312 mM, PDE3B
Angiotensin III
-
-
apigenin
-
IC50: 0.0105 mM, PDB3; IC50: 0.0167 mM, PDB2; IC50: 0.0254 mM, PDB1
BAY 60-7550
BAY60-7550
inhibition of isoform PDE2, results in increase in basal cGMP levels after application to thalamic neurons
Biochanin A
-
IC50: 0.0279 mM, PDE2; IC50: 0.0291 mM, PDE1
Caffeine
Calmidazolium
-
soluble but not particulate form
Chloropromazine
-
soluble but not particulate form
Cilostamide
cilostazol
cortisol
-
-
daidzein
-
IC50: 0.0286 mM, PDE3
dibutyryl cyclic AMP
dioclein
diosmetin
-
IC50: 0.0048 mM, PDB2; IC50: 0.0144 mM, PDB1
dipyridamole
E4021
-
50% inhibition at about 0.0005-0.001 mM
EHNA
-
a selective PDE2 inhibitor
eriodictyol
-
IC50: 0.0525 mM, PDB3
erythro-9-(2-hydroxy-3-nonyl)-adenine
-
IC50: 0.0092 mM, PDE2
erythro-9-(2-hydroxy-3-nonyl)adenine
etazolate
-
IC50: 0.0007 mM
ethylene glycobis(beta-aminoethyl ether)-N,N'-tetraacetic acid
-
soluble but not particulate form
-
felodipine
-
-
GDP
1 mM, 41% residual activity
genistein
-
IC50: 0.0017 mM, PDB2; IC50: 0.0129 mM, PDB3; IC50: 0.0168 mM, PDB1
GMP
1 mM, 31% residual activity
GTP
1 mM, 44% residual activity
isobutylmethylxanthine
linoleic acid
-
-
luteolin
-
IC50: 0.0101 mM, PDB3; IC50: 0.0133 mM, PDB2; IC50: 0.0215 mM, PDB1
luteolin-7-glucoside
-
IC50: 0.0351 mM, PDB2
methylxanthines
-
-
-
Milrinone
MP-10
-
-
myricetin
-
IC50: 0.0124 mM, PDB3; IC50: 0.0128 mM, PDB2; IC50: 0.0249 mM, PDB1
N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide
-
soluble but not particulate form
NADH
1 mM, 76% residual activity
NADPH
1 mM, 25% residual activity
NaF
1 mM, 79% residual activity
nicardipine
nimodipine
-
-
orthovanadate
-
PdeA shows 26% relative activity and PdeB shows 29% relative activity in the hydrolysis of 3',5'-cAMP in the presence of 0.05 mM orthovanadate
papaverine
Pb2+
-
at 2.5 mM
phosphate
-
PdeA and PdeB enzyme activities are strongly inhibited by 0.1 M sodium phosphate buffer (pH 6.0 and 7.0), the PdeB activity is more strongly inhibited by 0.1 M phosphate than is PdeA activity
phosphoserine
-
PdeA shows 59% relative activity and PdeB shows 73% relative activity in the hydrolysis of 3',5'-cAMP in the presence of 0.05 mM phosphoserine
phosphotyrosine
-
PdeA shows 44% relative activity and PdeB shows 52% relative activity in the hydrolysis of 3',5'-cAMP in the presence of 0.05 mM phosphotyrosine
PQ-10
-
-
quercetin
quercetin-3,5,7,3',4'-O-pentaacetate
-
-
quercetin-3,5,7,3',4'-O-pentamethylether
-
-
quercetin-3,7,3',4'-O-tetramethylether
-
-
quercetin-3,7,4'-O-trimethylether
-
ayanin
quercetin-3-O-methyl-5,7,3',4'-O-tetraacetate
-
-
quercetin-3-O-methylether
-
-
quinazolinamine
-
IC50: 0.01 mM, PDE3; IC50: 0.23 mM, PDE1; IC50: 0.241 mM, PDE2
rolipram
RP-73401
-
IC50: 0.05 mM, PDE3; IC50: 0.067 mM, PDE2; IC50: 0.13 mM, PDE1
sarilesin
-
-
sildenafil
SKF 94120
-
weak inhibitor
tadalafil
theophylline
TP-10
-
-
trequinsin
-
IC50: 0.0039 mM
Trifluoperazine
-
-
vardenafil
vinpocetine
zaprinast
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2-mercaptoethanol
-
stimulates
ascorbic acid
Ca2+
-
isoform PDE1, stimulation of both hydrolysis of cAMP and cGMP
Calmodulin
clozapine
-
chronic treatment with 20 mg/kg clozapine increases PDE10A expression by 62%
dithiothreitol
EDTA
-
reverses Ca2+ inhibition
ethylene glycol bis(beta-aminoethyl ether)-N,N'-tetraacetic acid
glutathione
haloperidol
-
chronic treatment with 1 mg/kg haloperidol increases PDE10A expression by 118%; chronic treatment with 1 mg/kg haloperidol increases PDE10A expression by 65%
imidazole
lipopolysaccharide
-
expression and activity of isoforms PDE2, PDE3, PDE11 in cultured peritoneal macrophages are recovered after treatment of cultured cells with lipopolysaccharide. Lipopolysaccharide also up-regulates enzyme expression in resident peritoneal macrophages
lysophosphatidylcholine
-
stimulation
lysophosphatidylethanolamine
-
stimulation
NH4+
-
stimulates
phosphatidylinositol
-
stimulation
stearate
-
stimulation
Subtilisin
-
stimulation, slightly more effective than trypsin
-
Trypsin
-
activation
-
additional information
-
not influenced by treatment with clozapine
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0038 - 0.0052
2',3'-cAMP
0.000079 - 7
3',5'-cAMP
0.00002 - 12.82
3',5'-cGMP
0.0014 - 0.0016
5'-AMP
0.0033 - 0.0125
5'-ATP
0.012
adenosine 3',5'-cyclic phosphate
-
pH 7.0, 55C
0.00023 - 1.6
cAMP
0.0002 - 1
cGMP
0.025
guanosine 3',5'-cyclic phosphate
-
pH 7.0, 55C
additional information
additional information
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0006 - 0.00096
2',3'-cAMP
0.00093 - 21
3',5'-cAMP
4.2 - 15.1
3',5'-cGMP
0.0031 - 0.00551
5'-AMP
0.00155 - 0.00454
5'-ATP
567
cAMP
Bos taurus
-
stimulation with Mg2+ or Mn2+
667
cGMP
Bos taurus
-
stimulation with Mg2+ or Mn2+
additional information
additional information
Bos taurus
-
-
-
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
100 - 213
3',5'-cAMP
75 - 156
3',5'-cGMP
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000062
(-)-6-(3-(3-cyclopropyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone
-
-
0.0434
(Rp)-guanosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate
-
in 45 mM HEPES (pH 7.2), 20 mM MgCl2, and 4 mM MES, at 25C
0.0000003
2-cyclohexyl-2-methyl-N1-[3-(2-oxo-1,2-dihydro-6-quinolyl,oxy)propyl]-1-hydrazinecarboxamide
-
-
0.00002 - 0.00003
3',5'-cGMP
0.0003
5-(2-propoxyphenyl)-2,3-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
-
-
0.00000022
6-(3-(3-cyclooctyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone
-
-
0.000039 - 0.000056
cilostazol
0.00055 - 0.00062
dioclein
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0001 - 0.00028
(-)-6-(3-(3-cyclopropyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone
0.0043
(2R,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
Homo sapiens
-
IC50: 0.0043 mM, PDE2
0.0023
(2S,3R)-3-(7-amino-3H-imidazo[4,5-b]pyridin-3-yl)nonan-2-ol
Homo sapiens
-
isoform PDE2, pH and temperature not specified in the publication
0.000006 - 0.015
(2Z)-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one
0.052
1-(2-methylbenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.053
1-(2-methylbenzyl)-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.0097
1-(3-chlorobenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.0095
1-(3-chlorobenzyl)-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.016
1-(3-methylbenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.0023
1-(4-chlorobenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.0007
1-(4-chlorobenzyl)-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.0014
1-(4-methylbenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.0015
1-(4-methylbenzyl)-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.028
1-benzyl-7-(2-oxopropyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione
Cavia porcellus
-
-
0.00000034 - 0.1129
2-cyclohexyl-2-methyl-N1-[3-(2-oxo-1,2-dihydro-6-quinolyl,oxy)propyl]-1-hydrazinecarboxamide
0.000001
2-[[4-[4-pyridin-4-yl-1-(2,2, 2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline succinic acid
Rattus norvegicus
-
the IC50 of the compound for inhibition of PDE10A in vitro is less than 1 nM
-
0.02654 - 0.068
3-isobutyl-1-methyl-1H-purine-2,6(3H,7H)-dione
0.00000032 - 0.0523
6-(3-(3-cyclooctyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone
0.0152
8-methoxymethyl-isobutylmethylxanthine
Bos taurus
-
isoform PDE1 in basal-activated state, pH and temperature not specified in the publication
0.0167 - 0.0312
amrinone
0.0105 - 0.0254
apigenin
0.0279 - 0.0291
Biochanin A
0.0012
cAMP
Homo sapiens
-
IC50: 1200 nM, PDE11A4
0.000059 - 0.00056
cGMP
0.000027 - 0.221
Cilostamide
0.0002 - 0.0452
cilostazol
0.0286
daidzein
Cavia porcellus
-
IC50: 0.0286 mM, PDE3
0.00144 - 0.1
dioclein
0.0048 - 0.0144
diosmetin
0.00034 - 0.0069
dipyridamole
0.0525
eriodictyol
Cavia porcellus
-
IC50: 0.0525 mM, PDB3
0.0092
erythro-9-(2-hydroxy-3-nonyl)-adenine
Bos taurus
-
IC50: 0.0092 mM, PDE2
0.00061
erythro-9-(2-hydroxy-3-nonyl)adenine
Homo sapiens
-
IC50: 0.00061 mM for wild-type enzyme
0.0007
etazolate
Trypanosoma cruzi
-
IC50: 0.0007 mM
0.0017 - 0.0168
genistein
0.0043 - 0.0127
IBMX
0.0101 - 0.0215
luteolin
0.0351
luteolin-7-glucoside
Cavia porcellus
-
IC50: 0.0351 mM, PDB2
0.0001 - 0.007
Milrinone
0.0124 - 0.0249
myricetin
0.0032
nimodipine
Bos taurus
-
isoform PDE1, pH and temperature not specified in the publication
0.000036 - 0.025
papaverine
0.0056 - 0.0278
quercetin
0.002
quercetin-3,5,7,3',4'-O-pentaacetate
Cavia porcellus
-
PDE3
0.0047
quercetin-3,5,7,3',4'-O-pentamethylether
Cavia porcellus
-
PDE3
0.0228
quercetin-3,7,3',4'-O-tetramethylether
Cavia porcellus
-
PDE3
0.0041
quercetin-3,7,4'-O-trimethylether
Cavia porcellus
-
PDE3
0.0008
quercetin-3-O-methyl-5,7,3',4'-O-tetraacetate
Cavia porcellus
-
PDE3
0.0016 - 0.0869
quercetin-3-O-methylether
0.01 - 0.241
quinazolinamine
0.15
rolipram
Homo sapiens
-
IC50: 0.15 mM for wild-type enzyme
0.05 - 0.13
RP-73401
0.00012 - 0.0038
sildenafil
0.000015 - 0.01
tadalafil
0.0039
trequinsin
Trypanosoma cruzi
-
IC50: 0.0039 mM
0.000121 - 0.00084
vardenafil
0.0223 - 0.185
vinpocetine
0.0016 - 0.071
zaprinast
0.01
additional information
Homo sapiens
-
IC50 for vardenafil, sildenafil and tadalafil is above 10000 nM, PDE2
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.0207
-
substrate cGMP, pH 7.0, 55C
0.0309
-
substrate cAMP, pH 7.0, 55C
0.36
-
-
1.33
-
-
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7
-
assay at
7.5 - 8.5
-
for 3',5'-cAMP with 0.1 M Tris-HCl buffer
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5 - 9
-
PdeB shows no 3',5'-cAMP phosphodiesterase activity at or below pH 6
7 - 8
more than 80% of maximum activiy
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
40
-
the optimum temperature for the 3',5'-cAMP phosphodiesterase activity of PdeA is 40C
55
-
assay at
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
pI VALUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5.5
calculated
5.9
-
calculated from sequence
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
glioblastoma cell, expression of isoform PDE1C and lower levels of isoforms PDE2, PDE3, PDE4, and PDE5
Manually annotated by BRENDA team
-
lung epithelial cell
Manually annotated by BRENDA team